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Editorial: Reconstruction of Brains and Journals
This issue begins a new incarnation of the
Journal ofNeural Transplantationand Plasticity
(JNTP). New journals, new editorships, and
major changes are often the occasion for the writ-
ing of editorials; this time, it is a new editorship
and a clarification of purpose. With this issue,
JNTP is re-dedicated to the publication of high-
quality studies of neural transplantation and plas-
ticity. JNTP will aim to become a leadingjournal
in the field by maintaining high standards of qual-
ity and a deafly-focused mission.
The editors and publisher especially wish to
thank Drs. Uri Yinon and Paul Sanberg for their
prior service as editor-in-chief and interim editor
respectively. Paul Sanberg has agreed to continue
to serve as a member of the editorial board.
Through their efforts, JNTP has become estab-
lished and developed a record of consistent publi-
cation of quality papers.
THE MISSION OF JNTP
The mission ofJNTP is to serve as a forum for
studies on manipulating, promoting, or guiding
neural plasticity. Neural transplantation, at the
moment, accounts for a large part of this litera-
ture. Due to recent advances in molecular biol-
ogy, it appears likely that intervention in brain
circuitry through administration or manipulation
of growth factors will in the near future at least
equal transplantation as a major area of research.
Other similarly promising methods of manipulat-
ing neural plasticity include, for example, altering
the substrate for neural growth/2, 11, 50/, im-
plantation of encapsulated cells/1, 70/and poly-
mers or gel matrices /71/, use of chronic
drug-releasing polymers/3, 23, 40/, and genetic
manipulation of neuronal cells in situ/24/. The
niche for JNTP is to communicate studies of
neural transplantation as well as neural plasticity,
especially studies of neural plasticity that are
relevant to experimental manipulation. This
would include studies in areas such as effects of
trophic factors, production of trophic or growth-
inhibitory factors by brain/41/, recovery of func-
tion after lesiom, including studies of reorganiza-
tion of neural circuits/51/, effects of behavioral
training/66, 68/and drugadministration/6,12, 28/,
survival or replacement of neuronal circuits, and
enhancement or guiding of collateral sprouting or
axonal regeneration, or studieswhich shed lighton
possibilities for such techniques.
In addition to its use as a means of manipulat-
ing brain function, neural transplantation has im-
portant applicatiom as a basic research tool. The
functional role of circuits in the brain has for the
most part been defined by the consequences of
their absence, following either experimental or
accidental lesiom. Neural transplantation is
unique as a research tool in that scientists can
begin to discern the functional contributiom of
newly comtructed or permanently modified neu-
ral circuits. When used as a basic research tool,
transplantation can help to explore the role of
neuronal circuits by allowing for both removal
(lesioning) and replacement (transplantation).
Neural transplantation also serves as a method
withwhich to studybrain development, and canbe
a valuable tool for studying the processes of neu-
ronal migration and segregation/59/and the for-
mation of synaptic connectiom. Studies on these
topics would also be within the scope ofJNTP.
POTENTIALAPPLICATIONS IN
MODELS OF DISEASE
There is, of course, ahope that transplantation
or techniques for manipulation ofneural plasticity
which have been developed in animal models will
ultimately be useful to treat degenerative disease
or injury in humans. For the most part, a rational
and systematic development of appropriate ani-
mal models, and subsequently potential modes of
therapy, for any disease requires that first the
neuronal mechanisms and circuits which are in-
volved be understood at least to some degree.
Secondly, the relatiomhips between these circuits
and the disease itselfmust be found. Usually, this
understanding can only be gained by basic studies
of neuronal circuits in animals, followed by post-
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mortem biochemical studies, histopathology, or
potentially neural imaging studies ofthese circuits
in living subjects. Finally, once a picture of the
disease process has developed, clinical manipula-
tion can be planned rationally. When clinical in-
tervention is considered, ideally, transplantation
will in time be only one of an array of methods
which can be used to effect localized changes in
the functioning ofneuronal circuits. Intervention
to alterneuronal plasticitymight takemany forms,
including pharmacological treatments, localized
administration of support matrices or growth fac-
tors, genetic manipulations, or behavioral training
/20/.
Possibly the most direct form of manipulation
ofneural plasticity is to promote endogenous neu-
rons to grow or form new connections. It may be
possible to enhance the plasticity of mature neu-
rons by genetic reprogramming, but it may also be
possible to accomplish the same goal more simply
by the administration of exogenous substances,
generically "growth factors". The prototype
growth factor, nerve growth factor (NGF), has
been known and studied for decades/33/. NGF
has a specific influence on peripheral sympathetic
and sensory neurons and on central cholinergic
neurons. Until recently, there have been rela-
tively few studies of the effects of administration
ofNGF. In the past few years, however, possibil-
ities for theuse ofNGF administration to enhance
functional recovery from lesions, sparing of neu-
rons following axotomy, and prevention ofdegen-
eration have begun to appear/29, 34/. The most
likely avenues for potential therapeutic effects of
NGF are in peripheral neuropathy and
Alzheimer’s disease. Advances in growth factor
identification through molecular biology have led
to the clarification of what has long been sus-
pected, that an entire class of neurotrophins,
growth factorswithvarying specificity for different
neuronal populations, exists. In fact, numerous
substances belonging to a variety of classes of
proteins have neurotrophic activity under various
circumstances. Availability of these proteins in
pure form has greatly facilitated studies of effects
of their administration. Neurotrophic factors can
be employed in a variety of strategies; they can be
administered directly to the brain, or peripherally
in models of peripheral neuropathy, or they can
perhapsbeused to enhance the effects ofneuronal
tissue transplants. There are complex issues asso-
ciated with methods of administration of proteins
to living organisms. Possibilities for administra-
tion include chronic injection, administration
through various kinds of chronic infusion pumps,
incorporation into gels or slow-release matrices,
and elicitation of expression of growth factors by
endogenous/24/or transplanted/14, 54/cells.
The second majorform ofmanipulation ofneu-
ral plasticity is neural transplantation. The "pro-
totype" disorder for neural transplantation,
Parkinson’s disease, is in that position because the
nature of the affected neuronal circuits is largely
known. Conceptually, the goals oftransplantation
research inParkinson’s disease, both clinicallyand
in animal models, are clear: replacement of the
dopaminergic afferentation of the neostriatum.
Most of the efforts in this area have been concen-
trated on three tissue sources, each with quite
different origins: These include: (a) transplama-
tion of fetal substantia nigra into the striatum or
lateral ventricles/4, 17, 19, 65/, (b) the use of
adrenal medulla as an alternate source of cate-
cholamine-producing cells/21, 63/with possible
trophic effects as well/5, 45, 48/, and (c) the use of
catecholaminergic cell lines/1, 15, 30/. There
have been a substantial number ofhuman clinical
trials ofboth adrenal medulla and substantia nigra
transplantation/16, 27, 35-37/. Some relatively
modest improvements have been observed in
most of the clinical trials. Limitations of clinical
trials of adrenal medulla grafts have included a
gradual loss of improvemems/43/, a high fre-
quency of side-effects including death, as well as
psychological disturbances and dementia/38, 44/,
and inconsistent graft survival/47/. For clinical
trials of embryonic SN grafts, the results are
generally promising, especially regarding the
apparently smaller frequency of side effects.
Nevertheless, the degree of improvement seen in
human subjects after SN grafts is generally mod-
est, and so far not qualitatively greater than the
effects of adrenal medulla grafts. Improvements
in the performance of transplantation procedures
may arise, for example, from advances in surgical
technique/9, 10/or improvement of the perfor-
mance of grafts through the administration of
growth factors/62/or co-transplantation of tissues
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which may secrete growth factors/8, 22, 32, 67/.
Efforts to develop new sources of dopamine-pro-
dueing cells, through immortalization/7, 25, 55/or
other genetic alteration ofcells/15, 30/, derivation
of cells from tumors/39/, and perhaps the use of
cells generated from the brainthrough other tech-
niques/49, 52, 53/are alsoguidedby thesame goal,
of finding improved methods of replacing the
dopaminergie system.
Additional possibilities for application of
transplantation and administration of growth fac-
tors inmodels of disease are likely to emerge over
the course of time. For neural transplantation,
two other notable possibilities have recently
emerged, in particular chronic pain syndromes
/56, 57/and Huntington’s disease/26, 31, 64, 69/.
Interesting possibilities have also been raised in
connection with application of transplantation to
more complex animals models/42/. Although
possibilities for applications to other clinical dis-
orders are more remote, research is being con-
ducted in a number of different areas. For
example, studies on transplantation in the visual
system and in models of cortical injury are repre-
sented by papers in this and other recent issues of
JNTP/13, 46, 58, 60/. Peripheral neuropathies are
at present the most immediate candidates for clin-
ical application of growth factors for similar rea-
sons, e.g., because the goals ofpotential therapies
are clear. Such a clear picture is available for few
other disorders. Nevertheless, there are otherpo-
tential avenues for clinical applications. Clinical
trials of NGF administration in Alzheimer’s dis-
ease are currentlybeing conducted. It is probable,
however, that some neuronal degenerative disor-
ders will have properties which are not amenable
to manipulation according to any existing concept.
For these, the properties of the disorder, once
found, may indicate new therapeutic possibilities.
It is entirely possible that techniques for manipu-
lating brain plasticity, in any form, will find appli-
cation for diseases (e.g., schizophrenia) which are
as yet not at all understood.
The issues of application of therapy to humam
are complex and have not been considered sys-
tematically/18, 61/. It is generally acknowledged
that degree of risk and invasiveness bears a direct
relationship to the amount of justification and
degree of confidence in the procedure which
should be required. For example, there are cer-
tainly some avenues for manipulation that can be
employed following brain injury, evenwithout any
understanding ofthe neural circuits involved. The
most notable of these is behavioral training. It is
well established that behavioral training can do a
great deal to aid recovery following CNS damage
/66/,yetthereasomwhythe trainingworks and the
nature of the brain damage to be treated are not
yet understood. Where more complex or invasive
procedures are required, a more thorough ratio-
nale is certainly needed. As yet there are no sys-
tematic procedures for comidering rationales for
clinical procedures such as brain tissue transplan-
tation. JNTP hopes to become a major forum for
communication of information related to manip-
ulation of neural plasticity through transplanta-
tion and other techniques. This will include, in
addition to original research papers, scholarly dis-
cussion of issues related to the applicability and
justification for potentially invasive techniques.
QUALITY STANDARDS FORJNTP
JNTP will endeavor to publish research ofhigh
quality, specifically in terms of methodology, ex-
perimental design, clarity of logic, careful formu-
lation of conclusiom, appropriate statistics, and
research fundamentals. Issues such as coding of
samples, blind testing, random assignment of ani-
mals to groups, use of appropriate control groups,
and quantification of histological and histochemi-
cal data where appropriate will be especially em-
phasized. Editorial board members and referees
will be asked to pay particular attention to these
factors.
To give some concrete examples ofwhatwillbe
asked of the referees: For behavioral studies, ap-
propriate control groups will be expected and ex-
perimental designs willbe examined for the ability
to support the stated conclusiom. Studies which
are based on changes in histological and histo-
chemical parameters induced by experimental
manipulations (as opposed to descriptive histol-
ogy) will usually be expected to provide appropri-
ate quantitative data or other forms of objective
data presentation. Referees will be asked to as-
sess whether these data were collected in con-
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trolled and carefully designed experiments. Con-
clusions will be examined to determine whether
they can be supported by the choice of control
groups and experimental design. For clinical stud-
ies,where it is oftenimpossible to employ controls
or large numbers ofsubjects, experimental design
issues such as baseline testing, frequent assess-
ments, quantitative measurements of outcome,
and attention to problems such as separate testing
during "on" and "off" phases (in Parkinson’s dis-
ease) are even more important. In other cases,
such as studies of primates, where practical reali-
ties limit the experimental design, authors will be
expected to point out these limitations in their
conclusions.
Although manuscripts describing new and ex-
citing findings are certainly desired, these will be
published only if they also meet similar criteria of
quality. In fact, specialized studies which extend
upon, clarify, or refute an earlier study are espe-
cially sought after as candidates for publication in
JNTP. It is also important to note that quality is
not necessarily synonymous with completeness,
length, or even thoroughness. Short papers, and
briefcommunications are solicited aswell. Papers
that carefully address a single, restricted aspect of
a problem are encouraged provided that, within
their own limits, the work presented is of similar
high quality. Technical reports and papers de-
scribing new methods are also encouraged.
The journal is interested in publishing schol-
arly reviews, commentaries, and letters question-
ing issues related to neural transplantation and
methods of manipulating neural plasticity. Com-
mentaries and letters which question conclusions
of earlier studies or research areas, raise issues of
experimental design, either advocate or question
opportunities for human application, or address
controversial issues in neural transplantation and
plasticity are solicited. JNTP is particularly inter-
ested in reviews which examine the conclusions
and designs of earlier studies in detail. In general,
review papers should offer new conclusions, inte-
gration, or re-interpretations ofother studies. Re-
views which simply abstract or enumerate
previous experiments are not desired. Reviews
maybe submitted without prior arrangementwith
the editor-in-chief, although prior consultation
may increase the likelihood of acceptance.
The field of neural tissue transplantation and
manipulation of neuronal plasticity has become
one of the central specialties in neuroscience.
JNTP aims to become a first choice forum for
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